RECURSION PHARMACEUTICALS-A (RXRX) Stock Analyst Earnings Estimates
NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.18M 157.07% | 39.84M 291.36% | 44.575M 11.89% | 72.163M 61.89% | 94.414M 30.83% | 126.29M 33.76% | |
| EBITDA YoY % growth | -174.36M -117.46% | -233.97M -34.19% | -324.458M -38.68% | -410.839M -26.62% | -523.626M -27.45% | -509.615M 2.68% | |
| EBIT YoY % growth | -182.77M -115.99% | -245.73M -34.45% | -348.86M -41.97% | -411.272M -17.89% | -487.257M -18.48% | -466.319M 4.30% | |
| Operating Margin | -1,795.38% | -616.79% | -782.64% | -569.92% | -516.09% | -369.24% | |
| EPS YoY % growth | N/A | -1.37 -12.87% | -1.57 -14.60% | -1.62 -2.93% | -1.74 -7.57% | -1.46 15.80% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.44 -4.83% | -0.54 -38.62% | -0.55 -36.85% | -0.52 -53.00% | -0.56 -26.25% |
| Revenue Q2Q % growth | 19.424M 78.35% | 12.801M -7.20% | 12.087M -16.16% | 14.969M -42.61% | 23.426M 20.60% |
| EBITDA Q2Q % growth | -152.643M -104.81% | -212.058M -141.63% | -216.036M -156.58% | -187.68M -150.87% | -196.554M -28.77% |
| EBIT Q2Q % growth | -123.61M -24.95% | -131.386M -38.10% | -133.934M -33.21% | -134.794M -37.05% | -130.186M -5.32% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.34 20.93% | -0.36 | 0.02 | 4.76% |
| Q2 2024 Q2Q % growth | -0.40 -5.26% | -0.41 | 0.01 | 1.55% |
| Q1 2024 Q2Q % growth | -0.39 -14.71% | -0.43 | 0.04 | 9.68% |
| Q4 2023 Q2Q % growth | -0.42 -35.48% | -0.46 | 0.04 | 8.24% |
| Q3 2023 Q2Q % growth | -0.43 -22.86% | -0.39 | -0.04 | -9.50% |
| Q2 2023 Q2Q % growth | -0.38 | -0.38 | 0.00 | 0.47% |
| Q1 2023 Q2Q % growth | -0.34 -3.03% | -0.35 | 0.01 | 4.21% |
| Q4 2022 Q2Q % growth | -0.31 18.42% | -0.30 | -0.01 | -4.80% |
| Q3 2022 Q2Q % growth | -0.35 -25.00% | -0.39 | 0.04 | 9.10% |
| Q2 2022 Q2Q % growth | -0.38 -22.58% | -0.38 | 0.00 | 0.21% |
| Q1 2022 Q2Q % growth | -0.33 75.19% | 0.10 | -0.43 | -423.53% |
| Q4 2021 Q2Q % growth | -0.38 | -0.31 | -0.07 | -21.48% |
| Q3 2021 Q2Q % growth | -0.28 | -0.29 | 0.01 | 1.96% |
| Q2 2021 Q2Q % growth | -0.31 | -0.24 | -0.07 | -30.25% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 26.082M 147.62% | 30.44M | -4.358M | -14.32% |
| Q2 2024 Q2Q % growth | 14.417M 30.86% | 13.522M | 895K | 6.62% |
| Q1 2024 Q2Q % growth | 13.794M 13.68% | 12.903M | 891K | 6.91% |
| Q4 2023 Q2Q % growth | 10.891M -20.39% | 20.76M | -9.869M | -47.54% |
| Q3 2023 Q2Q % growth | 10.533M -19.96% | 13.127M | -2.594M | -19.76% |
| Q2 2023 Q2Q % growth | 11.017M 43.64% | 12.153M | -1.136M | -9.35% |
| Q1 2023 Q2Q % growth | 12.134M 127.65% | 14.734M | -2.6M | -17.65% |
| Q4 2022 Q2Q % growth | 13.68M 440.71% | 24.48M | -10.8M | -44.12% |
| Q3 2022 Q2Q % growth | 13.16M 420.16% | 7.115M | 6.045M | 84.96% |
| Q2 2022 Q2Q % growth | 7.67M 200.78% | 5.508M | 2.162M | 39.25% |
| Q1 2022 Q2Q % growth | 5.33M 108.20% | 85.629M | -80.299M | -93.78% |
| Q4 2021 Q2Q % growth | 2.53M | 6.188M | -3.658M | -59.11% |
| Q3 2021 Q2Q % growth | 2.53M | 2.754M | -224K | -8.13% |
| Q2 2021 Q2Q % growth | 2.55M 1,242.11% | 2.78M | -230K | -8.27% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -16.04% | 1.89% | 0.18% | -0.03% |
| Revenue | 4.8% | 4.8% | 1.07% | 7.43% |